Press release
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey concerning NF1-PN, a rare disease.
The report forecasts that the NF1-PN market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow from approximately USD 380 million in 2023 at a considerable CAGR by 2034. This anticipated growth is attributed to ongoing research into the genetic underpinnings of these tumors, the availability of medical therapy as an alternative to surgery, improvements in administration ease, and a decrease in side effect profiles of emerging therapies.
According to the report, the United States consistently holds the highest market share among the 7MM, with around USD 230 million in 2023.
The report provides a detailed epidemiological analysis and forecasts up to 2034, segmented by total NF1 diagnosed prevalent cases, diagnosed cases of NF1 manifestations, age-specific NF1-PN diagnosed cases, NF1-PN cases by clinical symptoms, and NF1-PN cases eligible for surgery in the 7MM. In 2023, the majority of diagnosed NF1-PN patients were estimated to be in the US, followed by Germany.
Current NF1-PN treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs from 2020 to 2034 are also addressed in the report. While surgery remains a standard treatment for many patients, it is often complex, not always feasible, carries inherent risks, and has a high possibility of tumor recurrence. A multidisciplinary approach involving genetics, neurology, radiology, and surgery, is vital for effectively managing the disease's physical and emotional impacts.
With an improved understanding of the genetic basis of plexiform neurofibromas, targeted therapies like the MEK inhibitor KOSELUGO (AstraZeneca and Merck) have emerged as promising options, especially for pediatric patients with inoperable NF1-PN. Building on this progress, researchers are exploring other MEK inhibitors for potential use in both pediatric and adult patients.
The current NF1-PN developmental pipeline includes additional MEK inhibitors such as Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Another emerging drug, HLX-1502 (Healx), offers a unique investigational treatment option for NF1 patients. In October 2024, the US FDA granted Fast Track Designation (FTD) to HLX-1502 for the treatment of NF1.
Recent developments include findings for PAS-004, which demonstrated no dose-limiting toxicities in Phase 1 clinical trials. An external Safety Review Committee recommended proceeding with its higher doses without modification in February 2025, highlighting the potential of these emerging therapies to revolutionize NF1-PN treatment.
Although NF1-PN presents significant challenges due to its highly individualized treatment needs-including multidisciplinary teamwork, tumor regrowth, and complications arising from tumors developing in critical areas like the head, neck, chest, or spine-the emergence of novel therapies as an alternative to surgery, improving administration ease and minimize side effects, is expected to broaden treatment options and enhance market growth.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF NF1-PN
4. NF1-PN EPIDEMIOLOGY AND MARKET METHODOLOGY
5. NF1-PN MARKET OVERVIEW AT A GLANCE
6. KEY EVENTS
7. NF1-PN BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND NF1-PN PATIENT POPULATION
9. NF1-PN PATIENT JOURNEY
10. NF1-PN MARKETED DRUGS
11. NF1-PN EMERGING DRUGS
12. NF1-PN: SEVEN MAJOR MARKET ANALYSIS
13. NF1-PN UNMET NEEDS
14. NF1-PN MARKET SWOT ANALYSIS
15. KOL VIEWS
16. MARKET ACCESS AND REIMBURSEMENT
17. APPENDIX
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Related Reports
Plexiform Neurofibroma Market Insight [https://www.delveinsight.com/report-store/plexiform-neurofibroma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Plexiform Neurofibroma Market Insight, Epidemiology And Market Forecast report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Plexiform Neurofibroma market trends, market drivers, market barriers, and key Plexiform Neurofibroma companies, including SpringWorks Therapeutics, Array BioPharma, Novartis, Shanghai Fosun Pharmaceutical Development Co, Ltd.,and Ashvattha Therapeutics, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-nf1pn-market-size-in-7mm-to-witness-notable-growth-expanding-from-usd-380-million-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight here
News-ID: 4128581 • Views: …
More Releases from ABNewswire
Schneider Electric Launches Veteran Hiring Initiative to Build Mission-Ready Wor …
Schneider Electric, a global energy technology leader, today announced a new initiative to recruit and train U.S. military veterans for careers in its Services business. The effort will create pathways for up to 400 technicians, including veterans, to join Schneider Electric's workforce in customer-facing service representative roles supporting data centers, energy systems, and other mission-critical facilities.
Demand for skilled technicians is at an all-time high as industries that power the global…
Verde Market Continues to Grow in the Heart of Brooklyn Expanding Departments an …
About Verde Market: Verde Market is a locally owned Brooklyn neighborhood grocery store offering fresh produce, organic foods, international products, and household essentials. Located in the heart of Prospect Heights, Verde Market is committed to sustainability, local sourcing, and supporting the vibrant Brooklyn community.
Brooklyn, NY - November 10, 2025 - Verde Market, located at 646 Dean Street, Brooklyn, NY 11238, continues to strengthen its roots as one of Brooklyn's favorite…
Report: How to Fix the Hidden Security Risks of Vibe Coding - and Why Platforms …
AI-generated code is fast, but often dangerously insecure. A new report published by the Finance Herald Highlights why vibe-coded apps built with tools like Replit, Cursor, Lovable, and Bolt are vulnerable, and how freelancers on platforms like Fiverr have become the go-to solution enabling builders to audit, patch, and secure your AI-built product before launch.
Key Takeaways
* AI-generated code is fast but fragile. Vibe coding tools such as Cursor, Lovable, Bolt,…
MoneyDoll: Detroit's New Powerhouse Blending Pop, R&B, and Hip-Hop With Soul and …
Rising star MoneyDoll is shaking up the music world with her fearless fusion of Pop, R&B, and Hip-Hop, combining the soulful heart of Detroit with the confidence of a modern global artist. Her breakout single "Cookies", available now on all major platforms, introduces a sound that's as catchy as it is commanding - smooth vocals, bold lyricism, and undeniable charisma.
Image: https://www.abnewswire.com/upload/2025/11/b227c2b8aa6d6c2ab59677d0cafbc0a3.jpg
Carrying the Legacy - and Redefining It
Born into musical royalty…
More Releases for NF1
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers…
Plexiform Neurofibroma Market to Grow at 9.7% CAGR from 2025 to 2034
Subheadline:
Rising research in neurofibromatosis type 1 (NF1), FDA approvals of MEK inhibitors, and emerging gene-editing therapies are driving strong global growth in the plexiform neurofibroma market.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72662
Introduction
The Plexiform Neurofibroma Market is entering a period of rapid expansion as precision medicine and genetic therapies reshape the management of neurofibromatosis type 1 (NF1) and related tumor growth disorders.
Valued at USD 410 million in 2024,…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
